Annoviant Awarded SBIR Phase II Grant from the NIH

Annoviant Awarded $1.85M SBIR Phase II Grant from the National Institutes of Health

Funding will help drive commercialization of next-generation pulmonary valve conduit for pediatric patients

ATLANTA--()--Annoviant LLC, formerly TGen Tech LLC, today announced that it has been awarded a grant of $1.85 million for two years by the National Institutes of Health (NIH) to help further its development and commercialization of the TxGuard™ pulmonary-valved conduit. This is a continuation of the Phase I Small Business Technology Transfer (STTR) grant the company received in 2019.

“We’re extremely pleased to receive this grant, and we are grateful for the National Heart, Lung, and Blood Institute’s financial support”

The new conduit represents breakthrough technology in conduit replacements for the treatment of congenital heart disease (CHD). Tailored largely toward pediatric patients, the device is designed to resist early degeneration and allows regeneration with host cells, enabling the device to grow with children.

CHD affects approximately 40,000 newborns each year in the U.S. Valve and conduit replacements are needed for absent pulmonary valve, aortic stenosis (Konno procedure, Ross, procedure), double outlet right ventricle (Rastelli operation), extracardiac conduit (Fontan operation), and pulmonary valve replacement (Tetralogy of Fallot).

“We’re extremely pleased to receive this grant, and we are grateful for the National Heart, Lung, and Blood Institute’s financial support,” said Ajay Houde, Ph.D., MBA, co-founder and CEO, Annoviant. “The grant funding will enable us to address the clinical and cost challenges associated with treating CHD in children.”

The primary issues currently observed with commercial devices are (a) calcification; (b) thrombosis; and (c) infection. Annually, 40,000 (U.S.) and 1.3 million (global) children are born with CHD, resulting in 4%-6% of neonatal deaths. According to the Centers for Disease Control and Prevention (CDC), there are about 2.9 million CHD patients in the U.S.

Pediatric patients with CHD typically undergo 3 to 5 cardiovascular surgeries over their lifetimes with an estimated total cost of $5.61 billion1 to the U.S. healthcare industry for treatment of CHD patients.

The TxGuard “scaffolding” exhibits clinical advantages over commercial products, specifically its cutting-edge qualities that make it resistant to calcification (plaques), thrombosis, and infection. Its ability to regenerate and grow with patients also is a significant distinguishing benefit.

About Annoviant

Annoviant LLC, formerly TGen Tech LLC, is a medical device company founded in 2018 and currently collaborating with a broad ecosystem, including research institutions and industry partners across the country. Fueled by personal experiences of its co-founders, the company is driven by a passion to make a positive difference in the lives and treatment of congenital heart disease (CHD) patients. The new TxGuard™ portfolio of devices can address the clinical challenges and significantly reduce healthcare costs by eliminating the required repeat surgeries. The company is developing cardiovascular devices for structural heart treatments.

NIH: Research reported in this news release was supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) under Award Number R44HL147771. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

1 https://www.cdc.gov/ncbddd/heartdefects/features/keyfindings-hospital-costs-resource-use.html

---

Originally published on BusinessWire.